Gaurav Aggarwal
CIK 1551965 · Chief Business Officer · last filed 2025-08-26
Gaurav Aggarwal is a Chief Business Officer who has filed 23 SEC Form 4 insider transactions across 4 companies since 2012. The most recent filing, for UNCY, was dated Aug 26, 2025. Across all open-market trades the lifetime net is +$21.6M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $7.1M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
SRRA price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
2440 SAND HILL ROAD, SUITE 302
MENLO PARK, CA 94025
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| UNCY | Director | 1,789,915 | $3.94 | $7.05M | $0 | 7 | 2025-08-26 |
| GERN | Director | 1,970 | $1.13 | $2.2K | $0 | 4 | 2025-05-22 |
| Sierra Oncology, Inc. (SRRA) Delisted | Director | 0 | $54.99 | $0 | $21.60M | 7 | 2022-07-01 |
| HYPERION THERAPEUTICS INC (HPTX) Delisted | Director | 5,000 | — | — | $50.0K | 1 | 2012-08-02 |
Recent Filings
23 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-08-26 | UNCY | Mixed | +652,900 | $0 | EDGAR |
| 2025-07-30 | UNCY | Grant (A) | — | $0 | EDGAR |
| 2025-05-22 | GERN | Grant (A) | — | $0 | EDGAR |
| 2025-02-19 | UNCY | Mixed | +1,400,000 | $0 | EDGAR |
| 2024-10-10 | UNCY | Mixed | +5,500,000 | $0 | EDGAR |
| 2024-05-10 | GERN | Grant (A) | — | $0 | EDGAR |
| 2024-01-03 | GERN | Grant (A) | +1,970 | $0 | EDGAR |
| 2023-11-28 | GERN | Grant (A) | — | $0 | EDGAR |
| 2023-09-07 | UNCY | Grant (A) | — | $0 | EDGAR |
| 2023-07-13 | UNCY | Conv (C) | +3,470,152 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.